Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
151. |
ECCT/15/12/05 | Post-discharge Malaria Chemoprevention(PMC) study Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial |
Principal Investigator(s) 1. Titus Kwambai 2. Simon Kariuki Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Homa Bay County Referral Hospital (Homa Bay county) 3. Migori County Referral Hospital (Migori county) 4. Busia County Referral Hospital (Busia county) |
View |
152. |
ECCT/15/12/02 | The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial A Multi Centre, Open label, Randomized Clinical Trial, Comparing HIV incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate, Levernogestrel (LNG) implant and Copper Intrauterine Devices (IUD). Short Title : The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial |
Principal Investigator(s) 1. Prof Elizabeth Anne Bukusi Site(s) in Kenya KEMRI-RCTP Study center , Lumumba |
View |
153. |
ECCT/15/11/01 | A5264 A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) |
Principal Investigator(s) 1. Dr. Victor Otieno Mudhune Site(s) in Kenya 1. KEMRI CDC (Kisumu county) |
View |
154. |
ECCT/15/08/01 | Rifapentine During Intensive Phase TB Treatment Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized, open-label, controlled, phase 3 clinical trial |
Principal Investigator(s) 1. Elisha Ochieng Okeyo Site(s) in Kenya KEMRICDC, KISUMU, KENYA |
View |
155. |
ECCT/15/06/03 | DolutegrAvir With NRTIs as second-line treatment (DAWNING) A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy |
Principal Investigator(s) 1. Dr. Evans Inyangala Amukoye 2. Dr. Maricianah Atieno Onono Site(s) in Kenya 1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county) 2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county) |
View |